NCT06225895

Brief Summary

Bilateral reduction mammoplasty is one of the most commonly performed breast surgery. The Postoperative pain following it should be minimized. Opioid administration for acute pain after reduction mammoplasty surgery has many side effects. Regional block techniques such as paravertebral block and thoracic epidural anesthesia have possible complications and technical difficulties. The new alternative regional techniques such as erector spinae plane block and rhomboid intercostal plane block are clinical trials for providing a safe, easy, and painless anesthetic procedure with adequate postoperative analgesia for a large section of patients undergoing thoracic surgeries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 17, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 26, 2024

Completed
6 days until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

July 17, 2025

Status Verified

July 1, 2025

Enrollment Period

6 months

First QC Date

January 17, 2024

Last Update Submit

July 14, 2025

Conditions

Keywords

Rhomboid Intercostal BlockErector Spinae Plane BlockReduction MammoplastyAnalgesia

Outcome Measures

Primary Outcomes (2)

  • Time to first dose of rescue analgesia

    is the time from the end of operation to patient reporting VAS ≥ 3. Thereafter, rescue analgesia in the form of 0.1mg/kg IV of nalbuphine will be injected.

    in the first postoperative 24 hours

  • Total nalbuphine consumption

    total dose of nalbuphine rescue analgesic that the patient required postoperatively

    in the first 24 hours postoperatively

Secondary Outcomes (2)

  • changes of pain assessment

    at 1hour, 3,6,12, 24 hours postoperatively

  • non invasive blood pressure

    immediately prior to surgery, immediately after skin incision, 15,30,60,120,180,240 min intraoperatively and at end of surgery

Study Arms (3)

control group

PLACEBO COMPARATOR

patients will receive general anesthesia

Procedure: general anesthesia

E group

ACTIVE COMPARATOR

patients will receive Erector spinae plane block

Procedure: general anesthesiaProcedure: Erector spinae plane blockDrug: Bupivacaine

R group

ACTIVE COMPARATOR

patients will receive rhomboid intercostal nerve block

Procedure: general anesthesiaProcedure: a rhomboid intercostal nerve blockDrug: Bupivacaine

Interventions

patients will receive general anesthesia.

E groupR groupcontrol group

patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.

E group

patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.

R group

20 ml of bupivacaine 0.25%

E groupR group

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsThis surgery is only performed for women
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient acceptance.
  • Age 18-65 years old.
  • BMI ≤ 35 kg/m2
  • ASA I - II.
  • Elective bilateral reduction mammoplasty surgery under general anesthesia.
  • Duration of surgery within five hours

You may not qualify if:

  • Patients on anti-platelet, anticoagulant, or B blocker drugs.
  • Patients with acute decompensated heart failure, hypertension, heart block, coronary disease, Asthma
  • History of allergy to the local anesthetics (LA) agents used in this study,
  • Skin lesion at the needle insertion site,
  • Those with bleeding disorders, sepsis, liver disease, psychiatric disorders, and pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Faculty of medicine, zagazig university

Zagazig, Alsharqia, 4115, Egypt

Location

Shereen E Abd Ellatif

Zagazig, Alsharqia, 4115, Egypt

Location

Related Publications (5)

  • Gad M, Abdelwahab K, Abdallah A, Abdelkhalek M, Abdelaziz M. Ultrasound-Guided Erector Spinae Plane Block Compared to Modified Pectoral Plane Block for Modified Radical Mastectomy Operations. Anesth Essays Res. 2019 Apr-Jun;13(2):334-339. doi: 10.4103/aer.AER_77_19.

    PMID: 31198256BACKGROUND
  • Viscardi JA, Oranges CM, Schaefer DJ, Kalbermatten DF. Reduction Mammoplasty: A Ten-Year Retrospective Review of the Omega Resection Pattern Technique. J Clin Med. 2021 Sep 27;10(19):4418. doi: 10.3390/jcm10194418.

    PMID: 34640438BACKGROUND
  • Elsharkawy H, Saifullah T, Kolli S, Drake R. Rhomboid intercostal block. Anaesthesia. 2016 Jul;71(7):856-7. doi: 10.1111/anae.13498. No abstract available.

    PMID: 27291611BACKGROUND
  • Tunay DL, Ilginel MT, Karacaer F, Biricik E, Tabakan I, Ozmete O. Bilateral Ultrasound-Guided Erector Spinae Plane Block for Perioperative Analgesia in Breast Reduction Surgery: A Prospective Randomized and Controlled Trial. Aesthetic Plast Surg. 2023 Aug;47(4):1279-1288. doi: 10.1007/s00266-023-03315-0. Epub 2023 Mar 16.

    PMID: 36928313BACKGROUND
  • Yayik AM, Ahiskalioglu A, Ates I, Ahiskalioglu EO, Cinal H. Ultrasound guided bilateral rhomboid intercostal block for breast reduction surgery. J Clin Anesth. 2019 Nov;57:38-39. doi: 10.1016/j.jclinane.2019.03.001. Epub 2019 Mar 6. No abstract available.

    PMID: 30851503BACKGROUND

MeSH Terms

Conditions

Agnosia

Interventions

Anesthesia, GeneralBupivacaine

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnesthesiaAnesthesia and AnalgesiaAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Shereen E Abd Ellatif, M.D.

    Faculty of medicine, zagazig university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Double (Participant, Outcomes Assessor) double-blinded(participants and outcome assessors)
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: computer generating random numbers, the patients will be allocated into three equal groups: Group C: (control group) patients will receive general anesthesia. Group E: patients will receive an Erector spinea plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia. Group R: patients will receive rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor of anesthesia and surgical intensive care

Study Record Dates

First Submitted

January 17, 2024

First Posted

January 26, 2024

Study Start

February 1, 2024

Primary Completion

August 1, 2024

Study Completion

September 1, 2024

Last Updated

July 17, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

planned after the completion of the study and publication

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
planned after the completion of the study and publication
Access Criteria
contact with principal investigatoR

Locations